Page 3 - Sciences Group News Today

The FDA has granted fast track designation to SLS009 for use as a potential therapeutic option in patients with relapsed or refractory acute myeloid leukemia.

Shares of Mobileye Global Inc. (NASDAQ: MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial results and initial 2024 guidance.<

NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel therapies for

By Colin Kellaher Shares of SELLAS Life Sciences Group tumbled nearly 30% in premarket trading Thursday after the clinical-stage biopharmaceutical company...

U.S. stocks traded mostly higher midway through trading, with the Dow Jones index gaining around 200 points on Thursday. The Dow traded up 0.55% to 37,635.05 while the NASDAQ rose 0.05% to 14,599.10. The S&P 500 also rose, gaining, 0.28% to 4,718.19.

U.S. stocks traded mixed this morning, with the Dow Jones index gaining around 50 points on Thursday. Following the market opening Thursday, the Dow traded up 0.15% to 37,487.49 while the NASDAQ fell 0.27% to 14,553.12. The S&P 500 also fell, dropping, 0.01% to 4,704.42.

NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical...

U.S. stocks traded mixed toward the end of trading, with the Dow Jones index gaining over 100 points on Thursday. The Dow traded up 0.33% to 37,554.56 while the NASDAQ fell 0.10% to 14,578.04. The S&P 500 also rose, gaining, 0.09% to 4,708.93.

- Primary Endpoint of Safety and Efficacy Met with Clinical Activity and Increased Survival Observed - - 70.3 Weeks Median Overall Survival for Patients Treated with Combination Therapy; Median...

-Primary Endpoint of Safety and Efficacy Met with Clinical Activity and Increased Survival Observed -